Prof. Dr. Volker Bruss
Institute of Virology
Ingolstädter Landstrasse 1
About 1/3 of the global human population is or has been infected with the hepatitis B virus (HBV) and 350 million people are persistent virus carriers being at risk to develop liver cirrhosis or liver cancer. An effective vaccine is available to prevent new infections. However, chronic infections and the resulting liver diseases are still serious medical problems and available therapies of limited efficacy. The development of new or the improvement of existing therapeutic concepts on a rational basis requires a deep knowledge of the biology of HBV on a molecular level. More »
Leider ist der Eintrag nur auf English verfügbar.